Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26533895 | 0.87 | ACACB (0.33) | ACACBBRD4AURKARPS6KB1AURKB | |
| SCHEMBL29674405 | 0.79 | ADORA3 (0.40) | — | |
| SCHEMBL22983976 | 0.79 | ADORA3 (0.40) | — | |
| SCHEMBL22704691 | 0.78 | — | — | |
| SCHEMBL8922716 | 0.77 | PRMT6 (0.36) | — | |
| SCHEMBL22577522 | 0.74 | ADK (0.34) | ACACB | |
| SCHEMBL26533904 | 0.74 | AURKA (0.31) | ACACBAURKARPS6KB1AURKB | |
| SCHEMBL26534380 | 0.74 | BRD4 (0.35) | ACACBBRD4AURKARPS6KB1AURKB | |
| SCHEMBL26534382 | 0.73 | GALR3 (0.41) | BRD4 | |
| SCHEMBL10239015 | 0.72 | PRMT6 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | ACACB 4462/4885BRD4 1598/4885AURKA 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.